→ The Pfizer vets at Confluence Life Sciences have agreed to be bought out by Aclaris $ACRS in a deal that comes with $20 million in cash and stock. The biotech’s lead product include CDD-450, a novel MK-2 pathway inhibitor, topical Janus kinase inhibitors, and IL2-inducible T-cell kinase inhibitor programs.
→ Pfizer is pumping $100 million into its operations in Sanford, NC as it expands manufacturing capability for gene therapies. The move will add 40 jobs at the campus. Pfizer bought out Chapel Hill-based Bamboo last year in a $700 million deal as it ramped up its focus on gene therapies.
→ There’s more bad news for Juno Therapeutics. Another law firm is taking aim at Juno in a class action suit, saying its failure to disclose deaths of patients in its notorious mid-stage study of JCAR015 had left investors exposed.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,000+ biopharma pros who read Endpoints News by email every day.Free Subscription